United Therapeutics Corp
NASDAQ:UTHR
United Therapeutics Corp
Gross Profit
United Therapeutics Corp
Gross Profit Peer Comparison
Competitive Gross Profit Analysis
Latest Figures & CAGR of Competitors
Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
United Therapeutics Corp
NASDAQ:UTHR
|
Gross Profit
$2.2B
|
CAGR 3-Years
17%
|
CAGR 5-Years
9%
|
CAGR 10-Years
8%
|
|
Abbvie Inc
NYSE:ABBV
|
Gross Profit
$36.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Gross Profit
$20.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Gross Profit
$19.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Gross Profit
$8.6B
|
CAGR 3-Years
16%
|
CAGR 5-Years
27%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Gross Profit
$11.3B
|
CAGR 3-Years
12%
|
CAGR 5-Years
13%
|
CAGR 10-Years
18%
|
See Also
What is United Therapeutics Corp's Gross Profit?
Gross Profit
2.2B
USD
Based on the financial report for Mar 31, 2024, United Therapeutics Corp's Gross Profit amounts to 2.2B USD.
What is United Therapeutics Corp's Gross Profit growth rate?
Gross Profit CAGR 10Y
8%
Over the last year, the Gross Profit growth was 23%. The average annual Gross Profit growth rates for United Therapeutics Corp have been 17% over the past three years , 9% over the past five years , and 8% over the past ten years .